Cross-protective efficacy of engineering serotype A foot-and-mouth disease virus vaccine against the two pandemic strains in swine

文献类型： 外文期刊

第一作者： Zheng, Haixue

作者： Zheng, Haixue;Lian, Kaiqi;Yang, Fan;Jin, Ye;Zhu, Zixiang;Guo, Jianhong;Cao, Weijun;Liu, Huanan;He, Jijun;Zhang, Keshan;Li, Dan;Liu, Xiangtao

作者机构：

关键词： Foot-and-mouth disease virus;ASIA topotype;Engineering foot-and-mouth disease virus;Protective efficacy

期刊名称：VACCINE （ 影响因子：3.641； 五年影响因子：3.816 ）

ISSN：

年卷期：

页码：

收录情况： SCI

摘要： Foot-and-mouth disease (FMD) is a highly contagious vesicular disease that affects domestic and wild cloven-hoofed animals worldwide. Recently, a series of outbreaks of type A FMDV occurred in Southeast Asian countries, China, the Russia Federation, Mongolia, Kazakhstan and South Korea. The FMD virus (A/GDMM/CHA/2013) from China's Guangdong province (2013) is representative of those responsible for the latest epidemic, and has low amino acid identity (93.9%) in VP1 protein with the epidemic strain A/WH/CHA/09 from Wuhan, China in 2009. Both of isolates belong to the Sea-97 genotype of ASIA topo-type. Therefore, the application of a new vaccine strain with cross-protective efficacy is of fundamental importance to control the spread of the two described pandemic strains. A chimeric strain rA/P1-FMDV constructed by our lab previously through replacing the P1 gene in the vaccine strain O/CHA/99 with that from the epidemic stain A/WH/CHA/09, has been demonstrated to exhibit good growth characteristics in culture, and the rA/P1-FMDV inactivated vaccine can provide protection against epidemic strain A/WH/CHAJ09 in cattle. However, it is still unclear whether the vaccine produces efficient protection against the new pandemic strain (A/GDMM/CHA/2013). Here, vaccine matching and pig 50% protective dose (PD50) tests were performed to assess the vaccine potency. The vaccine matching test showed cross-reactivity of sera from full dose vaccine vaccinated pigs with A/WH/CHA/09 and A/GDMM/CHA/2013 isolates, with average r(1) values of 0.94 +/- 0.12 and 0.68 +/- 0.06 (r(1) >= 0.3), which indicates that the rA/P1-FMDV vaccine is likely to confer good cross-protection against the two isolates. When challenged with two pandemic isolates A/WH/CHA/09 and A/GDMM/CHA/2013 strain, the vaccine achieved 12.51 PD50 and 10.05 PD50 per dose (2.8 mu g), respectively. The results indicated that the rA/P1-FMDV inactivated vaccine could protect pigs against both A/WH/CHA/09 and A/GDMM/CHA/2013 pandemic isolates. (C) 2015 Elsevier Ltd. All rights reserved.

分类号： R392

  • 相关文献

[1]Combined recombinant DNA vaccine results in significant protection against Mycobacterium tuberculosis. Pan, Y,Cai, H,Li, SX,Tian, X,Li, T,Zhu, YX. 2003

[2]Expression of truncated Babesia microti apical membrane protein 1 and rhoptry neck protein 2 and evaluation of their protective efficacy. Wang, Guanbo,Efstratiou, Artemis,Moumouni, Paul Franck Adjou,Liu, Mingming,Jirapattharasate, Charoonluk,Guo, Huanping,Gao, Yang,Suzuki, Hiroshi,Igarashi, Ikuo,Xuan, Xuenan,Cao, Shinuo,Zhou, Mo.

[3]Effects of different promoters on the protective efficacy of recombinant Marek's disease virus type 1 expressing the VP2 gene of infectious bursal disease virus. Li, Kai,Liu, Yongzhen,Liu, Changjun,Gao, Li,Zhang, Yanping,Gao, Yulong,Cui, Hongyu,Qi, Xiaole,Zhong, Li,Wang, Xiaomei.

[4]Protective efficacy of a novel recombinant Marek's disease virus vector vaccine against infectious bursal disease in chickens with or without maternal antibodies. Li, Kai,Liu, Yongzhen,Zhang, Yanping,Gao, Li,Liu, Changjun,Cui, Hongyu,Qi, Xiaole,Gao, Yulong,Zhong, Li,Wang, Xiaomei.

[5]Protective Efficacy of the Inactivated H5N1 Influenza Vaccine Re-6 Against Different Clades of H5N1 Viruses Isolated in China and the Democratic People's Republic of Korea. Zeng, Xianying,Deng, Guohua,Liu, Liling,Li, Yanbing,Shi, Jianzhong,Chen, Pucheng,Feng, Huapeng,Tian, Guobin,Chen, Hualan,Zeng, Xianying,Deng, Guohua,Liu, Liling,Li, Yanbing,Shi, Jianzhong,Chen, Pucheng,Feng, Huapeng,Tian, Guobin,Chen, Hualan,Liu, Jingli,Guo, Xingfu,Mao, Shenggang,Yang, Fan,Chen, Zhiyu.

[6]Protective efficacy of a high-growth reassortant swine H3N2 inactivated vaccine constructed by reverse genetic manipulation. Wen, Feng,Ma, Ji-Hong,Yu, Hai,Yang, Fu-Ru,Huang, Meng,Zhou, Yan-Jun,Li, Ze-Jun,Tong, Guang-Zhi.

[7]A safe and molecular-tagged Brucella canis ghosts confer protection against virulent challenge in mice. Qian, Jing,Bu, Zhaoyang,Lang, Xulong,Wang, Xinglong,Qian, Jing,Qian, Jing,Yan, Guangmou,Yang, Yanling,Wang, Xiuran.

[8]Deletion of the BAC sequences from recombinant meq-null Marek's disease (MD) virus increases immunosuppression while maintaining protective efficacy against MD. Su, S.,Cui, N.,Sun, P.,Cui, Z.,Li, J.,Li, H.,Li, Y..

[9]Evaluation of two strains of Mareles disease virus serotype 1 for the development of recombinant vaccines against very virulent infectious bursal disease virus. Li, Kai,Liu, Yongzhen,Liu, Changjun,Gao, Li,Gao, Yulong,Zhang, Yanping,Cui, Hongyu,Qi, Xiaole,Zhong, Li,Wang, Xiaomei.

[10]Recombinant duck enteritis viruses expressing major structural proteins of the infectious bronchitis virus provide protection against infectious bronchitis in chickens. Li, Huixin,Wang, Yulong,Han, Zongxi,Wang, Yu,Liang, Shulin,Jiang, Lu,Kong, Xiangang,Liu, Shengwang,Wang, Yulong,Hu, Yonghao.

[11]Protective efficacy of pVAX-RON5p against acute and chronic infections of Toxoplasma gondii in BALB/c mice. Zhao, Yu,Li, Zhong-Yuan,Chen, Jia,Liu, Shan-Shan,Zhu, Xing-Quan,Zhou, Dong-Hui,Zhao, Yu,Sun, Xiao-Lin,Li, Zhong-Yuan,Liu, Shan-Shan,Zhu, Xing-Quan.

[12]Protective Efficacy of an H5N1 Inactivated Vaccine Against Challenge with Lethal H5N1, H5N2, H5N6, and H5N8 Influenza Viruses in Chickens. Tian, Guobin,Chen, Hualan.

[13]Construction and immune effect of Haemophilus parasuis DNA vaccine encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in mice. Bei, Weicheng,Fu, Shulin,Ou, Jiwen,Tan, Chen,Chen, Huanchun,Bei, Weicheng,Zhang, Minmin,Liu, Jinlin. 2012

[14]CpG DNA enhances the immune responses elicited by the DNA vaccine against foot-and-mouth disease virus in guinea pigs. Li, GJ,Li, YJ,Yan, WY,Xu, QX,Wu, YQ,Xie, Y,You, YJ,Zheng, ZX. 2001

[15]Enhanced immunogenicity of multiple-epitopes of foot-and-mouth disease virus fused with porcine interferon alpha in mice and protective efficacy in guinea pigs and swine. Du, Yijun,Li, Yufeng,Jiang, Wenming,Wang, Xinglong,Tang, Bo,Cao, Jun,Wang, Xianwei,Jian, Ping,He, Hairong,Qi, Jing. 2008

[16]The codon usage model of the context flanking each cleavage site in the polyprotein of foot-and-mouth disease virus. Zhou, Jian-hua,Zhang, Jie,Chen, Hao-tai,Ma, Li-na,Ding, Yao-zhong,Liu, Yong-sheng,Pejsak, Zygmunt. 2011

[17]Induction of Partial Protection against Foot and Mouth Disease Virus in Guinea Pigs by Neutralization with the Integrin beta 6-1 Subunit. Zhang, Yan,Sun, Yingjun,Yang, Fan,Guo, Jianhong,He, Jijun,Wu, Qiong,Cao, Weijun,Lv, Lv,Zheng, Haixue,Zhang, Zhidong. 2013

[18]Recovery of infectious foot-and-mouth disease virus from full-length genomic cDNA clones using an RNA polymerase I system. Chang, Yanyan,Zheng, Haixue,Shang, Youjun,Jin, Ye,Wang, Guangxiang,Shen, Xiaoyan,Liu, Xiangtao. 2009

[19]Development and validation of a lateral flow immunoassay using colloidal gold for the identification of serotype-specific foot-and-mouth disease virus O, A and Asia 1. Jiang, Tao,Liang, Zhong,Ren, Weiwei,Chen, Juan,Zhi, Xiaoying,Qi, Guangyu,Yang, Yamin,Liu, Zaixing,Liu, Xiangtao,Cai, Xuepeng,Ren, Weiwei,Zhi, Xiaoying,Qi, Guangyu. 2011

[20]An increased replication fidelity mutant of foot-and-mouth disease virus retains fitness in vitro and virulence in vivo. Zeng, Jianxiong,Wang, Haiwei,Xie, Xiaochun,Yang, Decheng,Zhou, Guohui,Yu, Li.

作者其他论文 更多>>

微信小程序